TMP

Quick links to important sections

TMP

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of TMP

Trimethoprim (TMP): What Type of Antimicrobial Agent Is It?

Property Description
Active ingredient Trimethoprim
Form Oral tablet, Oral suspension
Pharmacological class Antibiotic; Dihydrofolate Reductase Inhibitor
General purpose Management of bacterial infection
Origin Synthetic compound

Trimethoprim (TMP) is a widely utilized synthetic antimicrobial agent classified within the antibiotic pharmacological class. This drug is used to manage bacterial infection throughout the body by controlling the growth of harmful germs. It is clinically recognized for its efficacy against a range of gram-negative and gram-positive pathogens frequently implicated in systemic infections.

The compound is chemically known as 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine and is entirely synthetic, not derived from natural sources. Trimethoprim belongs to the specific subgroup of drugs known as dihydrofolate reductase inhibitors, which reflects its unique mechanism of action. This medicine helps manage infection by targeting the germs responsible for the illness, representing a reliable treatment option.


Composition, Forms, and General Therapeutic Purpose

Trimethoprim, as the sole active ingredient in its purest form, is typically delivered for systemic use in the body via common dosage form(s) such as oral tablets and a liquid oral suspension. The general therapeutic purpose of TMP is to halt the reproduction of bacteria, achieving a bacteriostatic effect.

This drug achieves its effect by selectively interfering with how bacteria utilize folic acid to produce the necessary components for their DNA and proteins, which is critical for their multiplication. This interruption stabilizes the bacterial infection by preventing the pathogen population from expanding. While effective alone as a monotherapy, Trimethoprim is frequently combined with the sulfonamide antibiotic sulfamethoxazole in a fixed-dose combination product, such as the widely known Bactrim or Septra formulations.

Regulatory References

  1. World Health Organization's (WHO) Essential Medicines List entry for Trimethoprim

What side effects are possible with TMP?

Possible Side Effects and Safety Information

The safety profile of Trimethoprim (TMP) is officially classified by regulatory documents, which categorize potential adverse reactions based on frequency and the body system affected. These classifications establish the reported range of safety characteristics, from commonly observed effects to rare but serious adverse reactions.

Officially documented adverse reactions are categorized into System-Organ Classes, including Blood and Lymphatic System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Metabolism and Nutrition Disorders. The frequency of effects is formally defined as:

  • Very Common (occurs in ge 1 in 10 patients): Hyperkalemia (high serum potassium levels).
  • Common (occurs in ge 1 in 100 to <1 in 10 patients): Nausea, vomiting, diarrhea, rash, and headache.

The regulatory label specifically outlines Serious Adverse Reactions, which include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Fatal or severe haematological disorders, including aplastic anemia, have also been officially documented as Very Rare events.

Safety considerations related to specific patient groups and exposure patterns are defined in the prescribing information. Older adults are noted to be more susceptible to certain effects, including severe skin reactions and hyperkalemia. Use is generally not recommended in infants younger than two months of age. Furthermore, interference with normal blood cell production is noted to be more probable with prolonged or high-dose use, emphasizing the context-specific nature of certain safety risks documented in the official regulatory profile.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for TMP

Overdose Scope

  • Documented Overdose Manifestations: Acute overdosage may be clinically observed as nausea, vomiting, dizziness, headache, mental depression, and confusion. Signs of chronic overdosage (high dose or prolonged use) manifest as indications of serious blood disorders, including sore throat, fever, pallor, or purpura.
  • Physiological Systems Affected: The primary documented risk is to the hematologic system, with severe outcomes including bone marrow depression and interference with hematopoiesis.
  • When Immediate Medical Help is Required: Immediate medical attention must be sought upon the suspicion of overdose or the observance of early clinical signs of serious blood disorders (e.g., fever, purpura).
  • Antidote and Supportive Management: The hematologic effects of overdosage are documented as reversible by folinic acid therapy (leucovorin). Management measures include gastric lavage or emesis, fluid administration, and procedures like acidification of the urine to enhance drug elimination.

Official Regulatory Statements

  • Overdosage is classified by regulators as carrying the potential for severe and life-threatening outcomes, particularly related to the blood and bone marrow.
  • Patient care involves mandatory extended monitoring with blood counts and blood chemistries, including electrolytes.
  • Patients with severely impaired renal function should be noted due to an increased risk of drug accumulation.

Connection to the Overall Overdose Profile

The official regulatory profile defines Trimethoprim overdose by connecting non-specific initial symptoms directly to the central, severe risk of bone marrow depression. The profile mandates immediate medical care upon symptom onset, detailing the use of folinic acid therapy as a specific treatment for the most dangerous documented complication and requiring mandatory procedural and monitoring steps to manage patient recovery.

Therapeutic Uses of TMP

Trimethoprim (TMP) is commonly used to help manage and relieve symptoms related to systemic imbalance associated with specific bacterial infections, primarily by offering supportive relief across key therapeutic domains.

What TMP Treats: Main Uses and Benefits

This medicine is applied when appropriate to help with conditions presenting with systemic or localized discomfort caused by susceptible bacteria. It is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as uncomplicated urinary tract infections (UTIs), management of recurrent symptomatic episodes, specific respiratory issues, and traveler's diarrhea.

The medication helps address symptom clusters that cause noticeable functional strain, like the painful burning and frequent urge to urinate associated with UTIs. For those experiencing repeated issues, it may be part of symptomatic management in situations involving recurrent or episodic manifestations.

“This medication contributes to improved comfort during periods of heightened symptoms.”

This supportive treatment assists with maintaining functional stability and helps patients cope more steadily with difficult episodes.

Quick Fact: Relief for Urinary Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Trimethoprim (TMP)

Official regulatory documents define strict criteria for patient eligibility to use Trimethoprim. Contraindications, which represent absolute prohibitions, include a known history of hypersensitivity to trimethoprim and the presence of documented megaloblastic anemia due to folate deficiency.

Eligibility by Age and Condition

Category Official Regulatory Status
Infants Contraindicated in pediatric patients less than 2 months of age.
Older Adults Use requires caution due to increased susceptibility to certain effects and potential decreases in renal or hepatic function.
Organ Function Severe renal insufficiency (CrCl less than 15 mL/min) and marked hepatic damage define populations who must not use the medicine.

Reproductive Status and Restrictions

Use of TMP is generally restricted during pregnancy, often classified as contraindicated or requiring careful evaluation, particularly in the first trimester. Trimethoprim is excreted into human milk, requiring caution and careful assessment during lactation. Regulatory labeling advises that eligibility is limited in patients with G6PD deficiency or other severe blood disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Trimethoprim (TMP) is officially documented by regulatory authorities, focusing on pharmacokinetic alterations, pharmacodynamic effects, and high-risk combinations.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Category Interacting Medicine or Class Official Interaction Pattern
High-Risk Contraindication Dofetilide Co-administration is formally contraindicated due to a significant increase in Dofetilide plasma concentrations.
Metabolic Inhibition Phenytoin TMP can inhibit the hepatic metabolism of Phenytoin, leading to officially documented increased plasma concentrations.
Electrolyte Balance ACE Inhibitors, ARBs, Potassium-sparing Diuretics An additive effect on serum potassium levels, resulting in an increased risk of hyperkalaemia.
Anti-Folate Effect Methotrexate, Pyrimethamine Additive anti-folate effects leading to an increased risk of haematological toxicity, such as bone marrow depression.
Clearance Alteration Digoxin, Procainamide TMP increases the plasma concentrations of these drugs by affecting their elimination and clearance mechanisms.
Coagulation Status Warfarin (Coumarins) May potentiate the anticoagulant effect of coumarins, as noted in official labeling.

Population-Specific Notes

The risk of thrombocytopenia with purpura is specifically noted to be increased in elderly patients who are concurrently taking thiazide diuretics. Patients with impaired renal function may experience an increased half-life of TMP, raising the risk of accumulation. The regulatory documents state that folates may be administered concurrently without inhibiting the antibacterial action of TMP.

Mechanism of Action

The core mechanism of Trimethoprim (TMP) is the selective competitive inhibition of the bacterial enzyme, Dihydrofolate Reductase (DHFR). This enzyme is critical for the conversion of dihydrofolate to tetrahydrofolate (THF), the biologically active cofactor required for bacterial metabolism. TMP exhibits a binding affinity to the bacterial DHFR that is thousands of times greater than for the analogous mammalian enzyme, ensuring targeted action. The resulting THF depletion initiates a cascade that starves the bacterial cell of essential one-carbon units. This specifically halts the biosynthesis of purines and thymidylate, which are the fundamental building blocks for DNA and RNA synthesis. The functional consequence of this intracellular arrest is a bacteriostatic effect—the cessation of bacterial cell division and replication. When combined with Sulfamethoxazole, a dual sequential blockade occurs, targeting two distinct points in the folate pathway, which results in mutual potentiation and a bactericidal action. The mechanism is limited by resistance due to genetic expression of a modified DHFR enzyme or the action of specialized efflux pumps that actively expel TMP from the cell.

Dosage and Administration Information

How to Use TMP (Trimethoprim/Sulfamethoxazole Combination) — Administration Guidelines

This section outlines the use of Trimethoprim/Sulfamethoxazole (TMP/SMX) based on standard clinical protocols and should not be considered medical advice.

Administration Routes and Forms

TMP/SMX is available in formulations for two primary routes of administration:

  • Oral: Available as tablets (standard and double strength) and an oral suspension.
  • Intravenous (IV) Infusion: Available as a concentrated injection solution that requires mandatory dilution before administration.

Dosing and Frequency

Population/Condition Standard Administration Rules
Standard Adults The standard regimen is typically one Double Strength (DS) tablet (160 mg TMP/800 mg SMX) taken every 12 hours (Twice Daily).
Pediatric Patients Dosing is calculated based on the child’s body weight (mg/kg/day of the TMP component) and divided into equal doses, often administered every 12 hours. Use in infants under 2 months of age is not recommended.
Renal Impairment Dosage must be adjusted or withheld based on the patient's Creatinine Clearance (CrCl).

Administration Conditions and Procedures

  • Oral Intake: Oral forms must be taken with a full glass of water. Patients are generally advised to maintain adequate fluid intake throughout the treatment course.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless the next scheduled dose is near. Do not take two doses at once.
  • IV Infusion: The injection concentrate must be diluted in a solution, typically 5% Dextrose in Water (D5W). It must be administered only by intravenous infusion over a period of 60 to 90 minutes. Rapid or bolus injection is not practiced.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research on Trimethoprim (TMP) and its common combination with Sulfamethoxazole (SMX) focuses on refining optimal dosing strategies and monitoring potential safety signals, particularly in vulnerable populations.


Dose Optimization and Effectiveness

Studies have assessed different dosing regimens for severe infections, such as Pneumocystis jirovecii pneumonia (PJP). Observational studies and ongoing Phase III trials are evaluating whether reduced doses (e.g., 10 mg/kg/day of the TMP component) may be associated with fewer adverse drug events (ADEs) compared to standard higher doses (15–20 mg/kg/day), without a significant difference in mortality for certain patients with PJP. For skin and soft tissue infections (SSTIs) caused by S. aureus, research has suggested that higher-dose regimens did not lead to increased clinical resolution rates compared to standard doses in the evaluated cohorts.


Safety Monitoring in Specific Populations

Recent population-based studies have focused on drug interactions, especially in elderly patients who may be on multiple medications. Research has found that the co-administration of TMP-SMX with certain heart medications, such as Digoxin, or diuretics like Spironolactone, may be associated with a significantly increased risk of hospitalization due to toxicity (e.g., hyperkalemia or Digoxin toxicity) compared to other antibiotics. Findings indicate that close monitoring of blood potassium and other drug levels is a critical consideration when this compound is prescribed to older adults with pre-existing conditions or those taking polypharmacy regimens.

Area of Research Key Finding Reported Patient Population
Dosing (PJP) Reduced doses associated with fewer ADEs in some studies. Immunocompromised adults
Safety Interaction Increased risk of hyperkalemia when combined with certain diuretics. Elderly patients
Pediatric Safety No demonstrated pediatric-specific safety issues from age two months and older. Children and young adults

Frequently Asked Questions (FAQ)

Common questions about TMP (FAQ)

Q: Can older adults use TMP safely?

According to official product information, older adults are generally identified as a population requiring caution. This is due to an increased risk of specific adverse effects, such as hyperkalemia (high potassium levels) and severe skin reactions, often related to potential declines in kidney or liver function. The need for close monitoring is often documented for this population.

Q: Why is TMP given to certain patients and not others?

The use of the medicine is officially defined by its efficacy against specific bacterial infections (known as Indications). Conversely, official documents prohibit its use (known as Contraindications) for patients with severe kidney or liver damage, megaloblastic anemia, or a known hypersensitivity to the drug.

Q: Does TMP need to be taken with food?

Official instructions for oral forms state that the medicine must be taken with a full glass of water. However, regulatory documentation does not specify whether taking the drug with or without food is required.

Q: Are there any long-term effects of taking TMP that people worry about?

Official information notes that the risk of certain haematological disorders, such as aplastic anemia or bone marrow depression, is more probable with prolonged or high-dose use. Regulatory documents also indicate that increased sun sensitivity is a documented effect that may require precautions during extended periods of use.

Q: Do I need to have regular blood tests while taking TMP?

Official documents describe periodic monitoring of blood components and kidney function as a documented consideration. This monitoring is important for patients receiving prolonged therapy, high doses, or who have pre-existing risk factors that could increase the likelihood of adverse events.

Q: Can I take TMP if I am sensitive to other medicines?

Eligibility criteria specifically restrict use in patients who have a known history of hypersensitivity or allergic reaction to trimethoprim itself, or other similar sulfonamide-type drugs. The official label does not address sensitivities to other, unrelated drug classes.

Q: How is the safety profile of TMP generally described?

The official safety profile is characterized by documenting adverse reactions in categories defined by frequency, from Very Common to Rare. This structured approach allows regulatory bodies to classify potential effects by severity, including specific warnings for serious skin reactions and hyperkalemia risk.

Q: Can TMP be taken with pain relievers like ibuprofen?

Regulatory documents list specific drug classes that interact with this medicine. For example, combining it with certain blood pressure medications or diuretics (e.g., ACE inhibitors or ARBs) is associated with an increased risk of hyperkalemia (high potassium). The official product list of interacting drug classes provides detailed information on co-administration.

Q: How long does it usually take for TMP to start working?

The regulatory profile describes the pharmacokinetics of the medicine, which includes the rate at which it reaches maximum concentration in the blood. For oral administration, this peak concentration is officially noted to occur within one to four hours.

Q: Is it normal to feel tired when first starting TMP?

The official adverse reaction lists include reports of effects on the nervous system. These documented effects, categorized by frequency, include headache, dizziness, lethargy, and general fatigue.

Q: Are there any foods or drinks I should avoid while taking TMP?

Regulatory warnings for the combination product (TMP/SMX) advise patients to avoid the concurrent use of alcohol. This is due to the potential for unpleasant side effects, such as flushing, fast heartbeats, nausea, or vomiting.

Q: Does TMP affect blood pressure?

Regulatory documents note the occurrence of serious, rare adverse events. These events include a risk of circulatory shock with associated hypotension (low blood pressure), primarily documented in immunocompromised patients.

Q: Can I take vitamins or supplements with TMP?

The official interaction profile states that folates (a specific type of supplement) may be administered concurrently. This is noted to occur without interfering with the antibacterial action of the medicine.

Q: Is there a generic version of TMP available?

According to regulatory bodies like the FDA, the combination drug (Sulfamethoxazole and Trimethoprim) is officially available in generic formulations. The availability of a generic version for TMP as a monotherapy is also documented.

Q: Can I drink alcohol in moderation while using TMP?

Regulatory warnings for the combination product (TMP/SMX) specifically advise patients to avoid the concurrent use of alcohol. This is based on the potential for unpleasant reactions, such as flushing, nausea, or fast heartbeats.

Q: Is TMP considered a long-term treatment?

The regulatory label defines the maximum approved durations for specific conditions. It notes that the risk of certain adverse effects is more probable with prolonged or high-dose use, which establishes context for treatment length.

Q: Is TMP known to cause changes in mood?

Psychiatric adverse reactions, such as depression, hallucinations, confusion, and agitation, have been reported in official documents. These are usually categorized as rare or very rare adverse events.

Q: Does TMP interact with birth control pills?

Official drug interaction information notes that combining this medicine with oral contraceptives (birth control pills) may make the contraceptive less effective.

Q: What if I'm planning to travel? Are there special considerations for TMP?

Official guidance on the use of this medicine focuses on storing it at controlled room temperature and protecting it from excess heat and moisture. These instructions are relevant for maintaining the integrity of the medicine during travel.

Q: Is TMP a controlled substance?

This medicine is officially classified as a Prescription Only drug by regulatory authorities. It is not designated as a controlled substance under the US Controlled Substances Act.

Q: Can men and women use TMP with similar expectations?

Restrictions on use are explicitly defined by reproductive status (pregnancy and lactation) due to risks documented in official documents. Beyond these specific reproductive factors, official documentation does not indicate differences in general safety expectations or effectiveness between adult men and non-pregnant adult women.

Q: Does TMP have a known connection to thyroid issues?

Hypothyroidism, or low thyroid levels, is reported as a rare potential adverse reaction in official documentation.

How should TMP be stored and disposed of?

Storage Requirements

Trimethoprim (TMP) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Regulatory labeling requires the product to be kept in the container it was dispensed in, tightly closed, and stored away from excess heat and moisture. The medicine must be kept from freezing under all circumstances.

Specific formulations, such as the oral suspension, must be protected from light. If using the oral suspension, any remaining product must be discarded 28 days after first opening.

Disposal and Child Safety

For safety, this medication must be stored out of the sight and reach of children and safety caps should always be locked. Unused or expired Trimethoprim must not be discarded via household waste or flushed down wastewater. Patients should follow official FDA guidelines or consult a pharmacist for instructions on proper disposal of unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of TMP found in:

A-Z Index: